EyeCRO are Experts in preclinical efficacy studies in ophthalmic retinopathy, pharmacokinetics, both in vivo and in vitro for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in retina preclinical efficacy, oxygen-induced retinopathy, and ophthalmic pharmacokinetics for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in Laser CNV, Retina preclinical efficacy, and Ophthalmic toxicology for clinical and precise formulation services.

Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research

MiDROPS™

The Microemulsion Drug Ocular Penetration System (MiDROPS™) is a transformative technology for the development of eyedrop formulations.  This patented platform allows for the preparation and delivery of lipophilic agents to tissues in both the front and back of the eye.  MiDROPS™ are prepared using materials already approved by the US Food and Drug Administration for use in ophthalmic products, and by nature are intrinsically thermo-stable.

In-Vivo

EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

Repair of Rhodopsin mRNA by Spliceosome-Mediated RNA Trans-Splicing: A New Approach for Autosomal Dominant Retinitis Pigmentosa

The promising clinical results obtained for ocular gene therapy in recent years have paved the way … Read More

Avalanche Biotechnologies and Annapurna Therapeutics Announce Proposed Merger

Avalanche Biotechnologies, Inc. (“Avalanche”) (AAVL) and Annapurna Therapeutics SAS (“Annapurna”), a … Read More

SBIR-STTR Success: Charlesson LLC/EYECRO

Macular Degeneration is the leading cause of blindness and vision loss in people over 50 –and with … Read More

More News

Saturday, February 6th, 2016 at 5:53am
Makes sense! We have been working on a stat3 inhibitor and here is a link between the two. https://t.co/nr9ihxKPK5 https://t.co/8VkMJFAAlW
Thursday, February 4th, 2016 at 6:44am
Breakthrough in generating embryonic cells that are critical for human health https://t.co/WWbkV9JdSj
Ophthalmic Contract Research